These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 20126863)

  • 1. Targeted molecular therapies in thyroid carcinoma.
    Romagnoli S; Moretti S; Voce P; Puxeddu E
    Arq Bras Endocrinol Metabol; 2009 Dec; 53(9):1061-73. PubMed ID: 20126863
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Harvesting the low-hanging fruit: kinase inhibitors for therapy of advanced medullary and nonmedullary thyroid cancer.
    Fagin JA; Tuttle RM; Pfister DG
    J Clin Endocrinol Metab; 2010 Jun; 95(6):2621-4. PubMed ID: 20525911
    [No Abstract]   [Full Text] [Related]  

  • 3. Novel molecular targeted therapies for refractory thyroid cancer.
    Perez CA; Santos ES; Arango BA; Raez LE; Cohen EE
    Head Neck; 2012 May; 34(5):736-45. PubMed ID: 21544895
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tyrosine kinase inhibitors and the thyroid.
    Sherman SI
    Best Pract Res Clin Endocrinol Metab; 2009 Dec; 23(6):713-22. PubMed ID: 19942148
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early clinical studies of novel therapies for thyroid cancers.
    Sherman SI
    Endocrinol Metab Clin North Am; 2008 Jun; 37(2):511-24, xi. PubMed ID: 18502340
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tyrosine kinase inhibitor treatments in patients with metastatic thyroid carcinomas: a retrospective study of the TUTHYREF network.
    Massicotte MH; Brassard M; Claude-Desroches M; Borget I; Bonichon F; Giraudet AL; Do Cao C; Chougnet CN; Leboulleux S; Baudin E; Schlumberger M; de la Fouchardière C
    Eur J Endocrinol; 2014 Apr; 170(4):575-82. PubMed ID: 24424318
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of advanced thyroid cancer: role of molecularly targeted therapies.
    Covell LL; Ganti AK
    Target Oncol; 2015 Sep; 10(3):311-24. PubMed ID: 26335853
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [New therapeutic options for advanced thyroid cancer].
    Willhauck MJ; Schott M; Kreissl MC; Fassnacht M; Spitzweg C
    Dtsch Med Wochenschr; 2011 Jun; 136(22):1165-8. PubMed ID: 21611920
    [No Abstract]   [Full Text] [Related]  

  • 9. Treatment with tyrosine kinase inhibitors for patients with differentiated thyroid cancer: the M. D. Anderson experience.
    Cabanillas ME; Waguespack SG; Bronstein Y; Williams MD; Feng L; Hernandez M; Lopez A; Sherman SI; Busaidy NL
    J Clin Endocrinol Metab; 2010 Jun; 95(6):2588-95. PubMed ID: 20392874
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rationale and clinical results of multi-target treatments in oncology.
    Sartore-Bianchi A; Ricotta R; Cerea G; Maugeri MR; Siena S
    Int J Biol Markers; 2007; 22(1 Suppl 4):S77-87. PubMed ID: 17520585
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Autophagic activation potentiates the antiproliferative effects of tyrosine kinase inhibitors in medullary thyroid cancer.
    Lin CI; Whang EE; Lorch JH; Ruan DT
    Surgery; 2012 Dec; 152(6):1142-9. PubMed ID: 23158184
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current status of molecularly targeted drugs for the treatment of advanced thyroid cancer.
    Takami HE
    Endocr J; 2011; 58(3):151-3. PubMed ID: 21383525
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thyroid dysfunction in patients treated with tyrosine kinase inhibitors, sunitinib, sorafenib and axitinib, for metastatic renal cell carcinoma.
    Daimon M; Kato T; Kaino W; Takase K; Karasawa S; Wada K; Kameda W; Susa S; Oizumi T; Tomita Y; Kato T
    Jpn J Clin Oncol; 2012 Aug; 42(8):742-7. PubMed ID: 22628612
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tyrosine kinase inhibitors in iodine-refractory differentiated thyroid cancer: experience in clinical practice.
    Molina-Vega M; García-Alemán J; Sebastián-Ochoa A; Mancha-Doblas I; Trigo-Pérez JM; Tinahones-Madueño F
    Endocrine; 2018 Feb; 59(2):395-401. PubMed ID: 29275532
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Medullary thyroid cancer: targeting the RET kinase pathway with sorafenib/tipifarnib.
    Hong D; Ye L; Gagel R; Chintala L; El Naggar AK; Wright J; Kurzrock R
    Mol Cancer Ther; 2008 May; 7(5):1001-6. PubMed ID: 18445656
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Nintedanib (BIBF 1120) in the treatment of solid cancers: an overview of biological and clinical aspects].
    Török S; Cserepes T M; Rényi-Vámos F; Döme B
    Magy Onkol; 2012 Sep; 56(3):199-208. PubMed ID: 23008829
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of anti-angiogenesis agents in treating NSCLC: focus on bevacizumab and VEGFR tyrosine kinase inhibitors.
    Cabebe E; Wakelee H
    Curr Treat Options Oncol; 2007 Feb; 8(1):15-27. PubMed ID: 17634832
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Systematic Review and Meta-analysis Comparing the Effectiveness and Adverse Effects of Different Systemic Treatments for Non-clear Cell Renal Cell Carcinoma.
    Fernández-Pello S; Hofmann F; Tahbaz R; Marconi L; Lam TB; Albiges L; Bensalah K; Canfield SE; Dabestani S; Giles RH; Hora M; Kuczyk MA; Merseburger AS; Powles T; Staehler M; Volpe A; Ljungberg B; Bex A
    Eur Urol; 2017 Mar; 71(3):426-436. PubMed ID: 27939075
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted therapy in advanced non-small-cell lung cancer.
    Gettinger S
    Semin Respir Crit Care Med; 2008 Jun; 29(3):291-301. PubMed ID: 18506667
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapy for metastatic RCC--questions remain.
    Breau RH; Leibovich BC
    Nat Rev Urol; 2009 Nov; 6(11):580-1. PubMed ID: 19890336
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.